|Bid||8.97 x 800|
|Ask||8.99 x 3000|
|Day's Range||8.90 - 9.13|
|52 Week Range||7.41 - 23.62|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a company with exceptional fundamental characteristics. Upon building...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...
Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.
Shares of biotech Intra-Cellular Therapies fell 15% in premarket trade Monday after the company announced disappointing results from a late-stage trial of its lead drug candidate lumateperone, a potential bipolar depression treatment. The trial, which evaluated 554 patients with bipolar disorder in the U.S., showed that lumateperone was no better than a placebo in helping to relieve symptoms of depression in patients with bipolar disorder. However, Intra-Cellular also announced positive results in a separate global trial of the drug looking at 381 patients with bipolar disorder from around the world. This Phase 3 trial met its primary endpoint; after six weeks of treatment, patients on the drug showed statistically-significant improvement over those on placebo. Intra-Cellular is also conducting a third trial of the drug, looking at it as an adjunctive therapy to lithium or valproate. In early July, Ritu Baral of Cowen said Intra-Cellular would need two positive trials to support filing a new drug application, or NDA. If both the U.S. and global trials looking at lumateperone showed positive results, the company would be able to file an NDA sometime in the second half of 2019, she wrote in a note to clients last week. But if only one of the trials was positive, the company would have to wait for data from the third trial -- evaluating lumateperone as an adjunctive therapy -- to come out. That data won't be available until 2020, she wrote. Shares of Intra-Cellular have gained 18.2% in the year to date through Friday, while the S&P 500 has gained 19.3%.
Intra-Cellular Therapies (NASDAQ: ITCI ) shares resumed trading after the company released mixed study results from two Phase 3 clinical trials evaluating lumateperone as monotherapy in the treatment of ...
Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of one of two late-stage studies in patients with major depressive episodes associated with bipolar disorder. The company's shares fell 6.5% before the opening bell. The treatment, lumateperone, which is being studied as a monotherapy for the condition, failed to show statistically significant improvement in the disease condition compared to placebo in the trial, the company said.
Intra-Cellular Therapies Inc. on Monday reported positive results from two late-stage trials of a treatment for bipolar depression. The New York-based company said the two phase 3 trials of lumateperone met their primary endpoints. In Study 404, that goal was change from baseline at week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo. Study 404 also met its key secondary endpoint, on the Clinical Global Impression Scale for Bipolar for Severity of Illness, or CGI-BP-S. That study produced positive results for patients with Bipolar type I and Bipolar type 2. "In Study 401, lumateperone did not separate from placebo," the company said in a statement. "A high placebo response was observed in the trial." Study 404 was conducted globally, including in the U.S. and included 381 patients. Study 401 was conducted only in the U.S. and involved 554 patients. "Consistent with previous studies in schizophrenia, lumateperone was well-tolerated in both bipolar depression studies, with a favorable safety profile," said the statement. Shares were halted for the news, but have gained 18.2% in 2019, while the S&P 500 has gained 19.3%.
Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week. Activity was light, although news on clinical trial readouts ...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
If you're interested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), then you might want to consider its beta (a...
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
The New York-based company said it had a loss of 63 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...